Pharmaceutical supply chain security is no longer a recommendation. DSCSA mandates serialized tracking from manufacturer to dispenser. DEA mandates documented chain of custody on every controlled substance. Cameras catch silhouettes. Digital Tripwire produces device-level proximity records that satisfy DSCSA verification, DEA diversion investigation, and insurer audit at the same time.
Pharmaceutical manufacturers and wholesale distributors operate inside the most heavily regulated commercial supply chain in the country. DSCSA mandates serialized tracking from manufacturer to dispenser. The DEA's CSA framework mandates documented chain of custody for every Schedule II-V transfer. FDA GMP standards mandate process documentation at every step. The full regulatory stack is built. None of it identifies the person who was actually present at the moment of a discrepancy.
The result is a chronic, multi-billion-dollar diversion problem flowing through the legitimate supply chain: employee diversion at manufacturing sites, warehouses, transport routes, and receiving docks. Counterfeit product introduction at wholesale handoffs. Cold-chain product theft. The serialized data shows what was logged. The proximity record shows who was standing there.
Digital Tripwire deploys at the regulated zones across pharma operations: manufacturing clean rooms, controlled substance vaults, Schedule II cages, cold-chain storage, packaging lines, transport docks, and the back-of-house corridors where inspectors look first. Deployment scales from a single warehouse to a global manufacturer with dozens of facilities feeding a unified pattern-matching layer.
When a node detects motion or proximity, it scans every Bluetooth and Wi-Fi device within 10 feet. MAC address, signal strength, timestamp. Uploaded over LTE-M cellular, independent of facility network or WMS. The log cross-references against DSCSA serialization events, DEA Form 222 transfers, ARCOS reporting, and warehouse transactions. The Schedule II cage discrepancy at 3:14am has a device cluster attached.
Strategic node placement covers the regulated zones across pharmaceutical manufacturing, wholesale distribution, 3PL, and specialty pharmacy operations. Designed for DSCSA, DEA, FDA, and NABP audit readiness. Tap a node to see what it protects — or run the demo and watch a Schedule II diversion get logged.
Inside the cage frame
DEA-mandated controlled substance vault. Every entry logged at device level and cross-referenced against Form 222 transfers, ARCOS reports, and perpetual inventory counts. The 3:14am discrepancy has a device cluster attached to it.
DEA Form 222 · ARCOS · CSOS
Inside the door frame
Biologics and vaccines at 2-8°C, -20°C, and ultra-low. Hardware rated for the full range. Proximity log runs alongside your temperature record, so a cold-chain breach has both a thermal trace and a person attached.
2-8°C to ULT rated · temp-record supplement
Inside the gowning area
GMP-classified production. Documents who entered the classified zone and when, without adding hardware to the production floor or disturbing the qualification envelope.
GMP zone · gowning threshold log
Inside the line frame
Serialization and labeling. The point where a DSCSA identifier is applied is the point counterfeit product is most cheaply introduced. The line logs who was standing at it.
Serialization event · label integrity
Inside the dock frame
DSCSA serialized shipments. The pallet the manifest says was loaded has a device record of who was at the bay when it moved.
T3 correlation · per-bay ID
Inside the lab frame
Sample handling and release. Controlled substance reference standards and retained samples live here, and they leave the same way everything else does.
Sample custody · release event
Inside the frame
The highest-fraud touchpoint in distribution. Saleable returns verification is where suspect product re-enters the legitimate chain, and where the device cluster matters most.
Saleable returns · suspect product
Inside the vault frame
High-value ingredients before they become product. Diversion here never shows up in serialization data, because the serial number does not exist yet.
Pre-serialization · high-value ingredient
The Drug Supply Chain Security Act took full enforcement effect in November 2024. Every prescription drug now carries a serialized identifier traceable from manufacturer to dispenser through electronic, interoperable transactions. Authorized trading partners verify authenticity at every transfer. Suspect product investigations are mandatory.
The proximity log cross-references against every T3 transaction, every saleable returns verification, and every suspect product investigation. The shipment that triggered a verification failure has a device cluster attached, with timestamp and signal strength documenting exactly who was at the dock. The distributor that shipped suspect product has a forensic record showing which employee handled the case at receiving and outbound.
Wholesale distribution of Schedule II-V controlled substances is the single most prosecuted pharma security failure mode of the past decade. DEA Diversion Investigators run unannounced facility audits. The penalty structure is catastrophic: license revocation, financial penalties in the tens to hundreds of millions, criminal exposure for facility leadership.
The pharmaceutical supply chain is governed by an interlocking stack of federal frameworks covering serialized track-and-trace, controlled substance handling, manufacturing process integrity, and wholesale distribution practices. A security vendor that does not understand the regulatory stack is a vendor that fails the first compliance review.
Digital Tripwire is engineered against the full federal stack. The export package, chain-of-custody framework, audit log, and deployment review process are built for the authorities your compliance officer already knows how to read. Insurance carriers recognize the system as a documented risk-mitigation control that can drive premium reduction at renewal. NABP VAWD reviewers and DEA Diversion Investigators see infrastructure that goes beyond minimum requirements.
We asked former FBI forensics investigators, federal prosecutors, and family court judges. They'd never seen BLE proximity data used as evidence. Until now.
DSCSA mandates electronic, interoperable verification at every transfer between authorized trading partners. The serialization data answers what was transferred. Digital Tripwire answers who was present at the moment of transfer, which is the gap DSCSA does not close. The proximity log cross-references against T3 transactions, saleable returns verifications, and suspect product investigations. During an FDA or state board investigation of a verification failure, the operator can produce both the serialization record and the device-level proximity record.
The Schedule II cage and every controlled substance handling zone is covered with proximity nodes producing hash-signed logs cross-referenced against DEA Form 222 transfers, ARCOS reports, CSOS electronic orders, and perpetual inventory counts. During a DEA Diversion Investigation or unannounced facility audit, the operator can produce a forensic device-level record of every entry to the cage, every shift transition, every counting event, and every transfer.
Cold-chain nodes are engineered for the temperature ranges required by biologics, vaccines, and specialty pharmaceutical storage (2-8°C, -20°C, ultra-low). The hardware operates reliably at these temperatures with extended battery life specifications. Deployment is reviewed alongside existing temperature monitoring, with the proximity log positioned as a supplement to the temperature record, not a replacement. Both data streams together produce a chain-of-custody record that satisfies temperature-sensitive product audit requirements.
The system captures MAC address proximity, signal strength, and timestamps in a federally-regulated, fully-monitored, badge-controlled facility where every employee already operates under documented monitoring frameworks established by the FDA, DEA, and state boards of pharmacy. The data does not capture identity, content, or personal information, and the proximity log has practical investigative value only when correlated with a security event, an inventory adjustment, or a regulatory inquiry. Standard signage and employee onboarding language are provided as part of deployment.
Carriers in the pharmaceutical space recognize documented physical security controls as risk-mitigation factors that can reduce premium at renewal. Operators with documented chain-of-custody records on every diversion event, every cold-chain breach, and every dock incident typically negotiate better terms on product liability, cargo, and crime policies. The deployment is documented as a control infrastructure addition during the next renewal cycle, with the carrier's risk engineering team supporting the evaluation.
Global deployments are designed for portfolio-wide rollouts across manufacturing, distribution, 3PL, and specialty pharmacy operations. Each facility gets a hub and a node kit sized to the regulatory zone classification and product mix. Hubs auto-provision over LTE-M on first power-up. No facility-level IT involvement required. Most pilots are 2-3 facilities (typically one manufacturing site and one distribution warehouse) for 90-180 days with cross-facility pattern matching enabled, then a phased rollout. International deployments are supported through regional cellular IoT and regional cloud infrastructure aligned with local frameworks (EU GDPR, EU FMD).
Operator pricing scaled to facility count and regulatory classification. Pilot 2-3 facilities in 90-180 days. DSCSA T3 correlation, DEA Form 222 alignment, cold-chain coverage, insurance-grade audit export, FDA and state board ready documentation.
Request a Pharma Briefing